304 related articles for article (PubMed ID: 31813299)
1. Site-agnostic biomarker-guided oncology drug development.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):583-592. PubMed ID: 31813299
[TBL] [Abstract][Full Text] [Related]
2. Evolving role of entrectinib in treatment of
Chawla N; Bui NQ; Seetharam M
Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
[TBL] [Abstract][Full Text] [Related]
3. TRK inhibitors in TRK fusion-positive cancers.
Drilon A
Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
[TBL] [Abstract][Full Text] [Related]
4. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
Delaye M; Rodrigues M
Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
[No Abstract] [Full Text] [Related]
5. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
[No Abstract] [Full Text] [Related]
6. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Seligson ND; Knepper TC; Ragg S; Walko CM
Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
[TBL] [Abstract][Full Text] [Related]
7. Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Hierro C; Matos I; Martin-Liberal J; Ochoa de Olza M; Garralda E
Clin Cancer Res; 2019 Jun; 25(11):3210-3219. PubMed ID: 30670489
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
Carlson JJ; Italiano A; Brose MS; Federman N; Lassen U; Kummar S; Sullivan SD
Am J Manag Care; 2022 Jan; 28(2 Suppl):S26-S32. PubMed ID: 35201681
[TBL] [Abstract][Full Text] [Related]
9. Tumour-agnostic drugs in paediatric cancers.
Chisholm JC; Carceller F; Marshall LV
Br J Cancer; 2020 May; 122(10):1425-1427. PubMed ID: 32161367
[TBL] [Abstract][Full Text] [Related]
10. Impact of the biomarker enrichment strategy in drug development.
Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
[TBL] [Abstract][Full Text] [Related]
11. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
Rohrberg KS; Lassen U
Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240
[TBL] [Abstract][Full Text] [Related]
12. Histology-agnostic drug development - considering issues beyond the tissue.
Pestana RC; Sen S; Hobbs BP; Hong DS
Nat Rev Clin Oncol; 2020 Sep; 17(9):555-568. PubMed ID: 32528101
[TBL] [Abstract][Full Text] [Related]
13. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
[TBL] [Abstract][Full Text] [Related]
14. A paradigm shift in biomarker guided oncology drug development.
Jørgensen JT
Ann Transl Med; 2019 Apr; 7(7):148. PubMed ID: 31157269
[TBL] [Abstract][Full Text] [Related]
15. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
16. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
17. How I treat
Lassen U
ESMO Open; 2019; 4(Suppl 2):e000612. PubMed ID: 31803506
[No Abstract] [Full Text] [Related]
18. Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services.
Walker A
J Oncol Pharm Pract; 2020 Dec; 26(8):2015-2019. PubMed ID: 32957860
[TBL] [Abstract][Full Text] [Related]
19. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
20. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]